BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nodality, Inc. Showcases Novel, Proprietary Technology to Predict Response to Therapy and Relapse Risk in Cancer Patients


12/7/2010 9:18:41 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., developing highly predictive tests to enable biologically informed clinical treatment decisions, today announced the presentation of promising data related to the application of the company’s novel, proprietary technology, Single Cell Network Profiling (SCNP) in hematologic malignancies. SCNP measures the activation levels of signaling networks at the single cell level by measuring the effects of multiple modulators, including drugs, on signaling pathways. This unique functional approach allows for the identification of the underlying heterogeneity in individual patient disease biology and enables efficient classification of patients into therapeutically relevant disease sub-populations by associating cell signaling with the pathogenesis of cancer. Data highlighting the clinical application of SCNP in patients with acute myeloid leukemia (AML) were presented today at the 52nd annual meeting of the American Society of Hematology (ASH) in Orlando, Florida.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES